This database contains 38 studies, archived under the term: "united states"
Click here to filter this large number of results.
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials
Manson, JoAnn E.,
Chlebowski, Rowan T.,
Stefanick, Marcia L.,
Aragaki, Aaron K.,
Rossouw, Jacques E.,
Prentice, Ross L.,
Anderson, Garnet,
Howard, Barbara V.,
Thomson, Cynthia A.,
LaCroix, Andrea Z.,
Wactawski-Wende, Jean,
Jackson, Rebecca D.,
Limacher, Marian,
Margolis, Karen L.,
Wassertheil-Smoller, Sylvia,
Beresford, Shirley A.,
Cauley, Jane A.,
Eaton, Charles B.,
Gass, Margery,
Hsia, Judith,
Johnson, Karen C.,
Kooperberg, Charles,
Kuller, Lewis H.,
Lewis, Cora E.,
Liu, Simin,
Martin, Lisa W.,
Ockene, Judith K.,
O’Sullivan, Mary Jo,
Powell, Lynda H.,
Simon, Michael S.,
Van Horn, Linda,
Vitolins, Mara Z.,
Wallace, Robert B.
Importance: Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.; Objective: To report a comprehensive, integrated overview of findings from the 2 Women’s Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.; Design, Setting, and Participants: A total of 27,347 postmenopausal women aged 50 […]
Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008
Lazzeroni, Laura C.,
Halbauer, Joshua D.,
Ashford, J. Wesson,
Noda, Art,
Hernandez, Beatriz,
Azor, Virgina,
Hozack, Nikki,
Hasson, Noelle,
Henderson, Victor W.,
Yesavage, Jerome A.,
Tinklenberg, Jared R.
Alzheimer’s disease (AD) shortens life-expectancy, but the effects of pharmacological treatments for this disorder on mortality have not been studied. We compared two commonly prescribed medications, donepezil and memantine, with respect to the length of survival of veterans presumed to have AD. The Computerized Medical Records System at the Veterans Affairs Palo Alto Health Care […]
A randomized trial of a CAM therapy for stress reduction in American Indian and Alaskan Native family caregivers
Korn, L.,
Logsdon, R. G.,
Polissar, N. L.,
Gomez-Beloz, A.,
Waters, T.,
Ryser, R.
Purpose: Although it is widely recognized that caregivers of individuals with dementia experience elevated stress that places them at increased risk for health problems, little is known about how caregiving stress may be alleviated among underserved ethnic minority populations. The purpose of this study was to compare a complementary and alternative medicine therapy, polarity therapy […]
Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study
Jackson, Graham S.,
Burk-Rafel, Jesse,
Edgeworth, Julie Ann,
Sicilia, Anita,
Abdilahi, Sabah,
Korteweg, Justine,
Mackey, Jonathan,
Thomas, Claire,
Wang, Guosu,
Schott, Jonathan M.,
Mummery, Catherine,
Chinnery, Patrick F.,
Mead, Simon,
Collinge, John
Importance: Our study indicates a prototype blood-based variant Creutzfeldt-Jakob disease (vCJD) assay has sufficient sensitivity and specificity to justify a large study comparing vCJD prevalence in the United Kingdom with a bovine spongiform encephalopathy-unexposed population. In a clinical diagnostic capacity, the assay’s likelihood ratios dramatically change an individual’s pretest disease odds to posttest probabilities and […]
Nursing homes and end-of-life care in Japan
Objectives: To describe end-of-life care in Japanese nursing homes by comparing facility and characteristics of residents dying in nursing homes with those who had been transferred and had died in hospitals, and by comparing the quality of end-of-life care with hospitals and with their respective counterparts in the United States.; Setting: National sample of 653 […]
Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors
Hebert, Paul L.,
McBean, Alexander Marshall,
O'Connor, Heidi,
Frank, Barbara,
Good, Charles,
Maciejewski, Matthew L.
Background: Centrally active (CA) angiotensin-converting enzyme inhibitors (ACEIs) are able to cross the blood–brain barrier. Small observational studies and mouse models suggest that use of CA versus non-CA ACEIs is associated with a reduced incidence of Alzheimer’s disease and related dementias (ADRD).; Objective: The aim of this research was to assess the effect of CA […]
The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors
Grossberg, George T.,
Manes, Facundo,
Allegri, Ricardo F.,
Gutiérrez-Robledo, Luis Miguel,
Gloger, Sergio,
Xie, Lei,
Jia, X. Daniel,
Pejović, Vojislav,
Miller, Michael L.,
Perhach, James L.,
Graham, Stephen M.
Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors.; Methods: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of […]